Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.38 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542598 | 1.00 | CHRM1 (0.44) | CHRM1ENPP2ATXN2SLC2A1KCNH2 | |
| SCHEMBL5543317 | 0.85 | CHRM1 (0.43) | CHRM1ALDH1A1NPSR1KDM4ETGM2 | |
| SCHEMBL5543324 | 0.85 | CHRM1 (0.43) | CHRM1ALDH1A1NPSR1KDM4ETGM2 | |
| SCHEMBL5544155 | 0.85 | CHRM1 (0.43) | CHRM1ALDH1A1NPSR1KDM4ETGM2 | |
| SCHEMBL5540981 | 0.82 | ENPP2 (0.40) | CHRM1ENPP2KCNH2 | |
| SCHEMBL5540976 | 0.82 | ENPP2 (0.40) | CHRM1ENPP2KCNH2 | |
| SCHEMBL6010758 | 0.80 | CHRM1 (0.38) | CHRM1SLC2A1KCNH2ALDH1A1TGM2 | |
| SCHEMBL6010751 | 0.80 | CHRM1 (0.38) | CHRM1SLC2A1KCNH2ALDH1A1TGM2 | |
| SCHEMBL6010853 | 0.80 | ALDH1A1 (0.41) | CHRM1KCNH2ALDH1A1MAPT | |
| SCHEMBL6010762 | 0.80 | ALDH1A1 (0.41) | CHRM1KCNH2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CHRM1 463/4885ENPP2 2915/4885ATXN2 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.